Structure Therapeutics: aleniglipron studies fully enrolled; Q4 net loss $36.5M, cash $883.5M

Structure Therapeutics Inc.

2024-FY EPS reported -$0.78

ACCESS and ACCESS II studies fully enrolled on schedule; topline 36-week data expected by year-end 2025.
Cash, cash equivalents and short-term investments $883.5M as of Dec 31, 2024; expected to fund operations through 2027.
Net loss Q4 2024 $36.5M ($24.5M Q4 2023); FY2024 net loss $122.5M ($89.6M FY2023).
Oral amylin agonist ACCG-2671: IND-enabling activities underway; Phase 1 initiation expected by year-end 2025.
R&D expenses increased to $33.5M for Q4 2024 from $20.0M; full year $108.8M from $70.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.